Literature DB >> 16274844

alpha-Melanocyte stimulating hormone, inflammation and human melanoma.

Paula C Eves1, Sheila MacNeil, John W Haycock.   

Abstract

Alpha-melanocyte stimulating hormone (alpha-MSH) arises from the proteolytic cleavage of proopiomelanocortin (POMC) and is the most potent naturally occurring melanotropic peptide. The biological effects of alpha-MSH are mediated via melanocortin receptors (MCRs), which are expressed in virtually every cutaneous cell type. alpha-MSH has pleiotrophic functions including the modulation of a wide range of inflammatory stimuli such as proinflammatory cytokines, adhesion molecules and inflammatory transcription factors. All of the former would be consistent with a cytoprotective role for this hormone in protecting skin cells from exogenous stress, as would occur following UV exposure or exposure to agents inducing inflammation or oxidative stress. In addition to actions on normal skin cells it also modulates both cutaneous and uveal melanoma cell behavior. With respect to melanoma, alpha-MSH is intriguing as studies have shown that while alpha-MSH has the potential to retard metastatic spread (by reducing cell migration and invasion) it is also capable of reducing the ability of the immune system to detect tumor cells (by down regulating adhesion molecules that would normally assist in immune cell interaction with melanoma cells). This review considers the evolving biology of alpha-MSH and discusses its role in man that extend far beyond pigmentation of skin melanocytes, suggesting that the detoxifying role of alpha-MSH in inducing melanogenesis is only one aspect of the stress-coping role of this hormone. Indeed melanoma cells may owe at least some of their success to the 'protective' role of alpha-MSH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274844     DOI: 10.1016/j.peptides.2005.01.027

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  17 in total

1.  Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.

Authors:  James P Cain; Alexander V Mayorov; Minying Cai; Hui Wang; Bahar Tan; Kevin Chandler; YeonSun Lee; Ravil R Petrov; Dev Trivedi; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2006-08-22       Impact factor: 2.823

Review 2.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

3.  Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism.

Authors:  Liang Dong; Ji Wen; Eric Pier; Xiao Zhang; Bo Zhang; Fangzheng Dong; Nick Ziegler; Margaret Mysz; Rafael Armenta; Rutao Cui
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

4.  Pharmacologic induction of epidermal melanin and protection against sunburn in a humanized mouse model.

Authors:  Alexandra Amaro-Ortiz; Jillian C Vanover; Timothy L Scott; John A D'Orazio
Journal:  J Vis Exp       Date:  2013-09-07       Impact factor: 1.355

Review 5.  Emerging role of alternative splicing of CRF1 receptor in CRF signaling.

Authors:  Michał A Zmijewski; Andrzej T Slominski
Journal:  Acta Biochim Pol       Date:  2010-03-16       Impact factor: 2.149

6.  Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression.

Authors:  Heesung Chung; Jung-hyun Lee; Dayun Jeong; Inn-Oc Han; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

7.  Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Authors:  Lihui Wei; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Amy L Vāvere; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

8.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

9.  The role of cytokines in the pathomechanism of cutaneous disorders.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2012-03       Impact factor: 1.494

Review 10.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.